Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

References

• Goldman JM, Melo JV. Chronic myeloid leukemic-advances in biology and new approaches to treatment. N Engl J Med 2003;349: 1451–1464.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S, et al.;International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–2541.
   PubMed Web of Science ®Google Scholar
• Crews LA, Jamieson CH. Chronic myeloid leukemic stem cell biology. Curr Hematol Malig Rep 2012;7:125–132.
   PubMed Web of Science ®Google Scholar
• Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011;121:396–409.
   PubMed Web of Science ®Google Scholar
• Perrotti D, Jamieson C, Goldman J, et al. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest 2010;120:2254–2264.
   PubMed Web of Science ®Google Scholar
• Huntly BJ, Shigematsu H, Deguchi K, et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004;6:587–596.
   PubMed Web of Science ®Google Scholar
• Kharas MG, Lengner CJ, Al-Shahrour F, et al. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemic. Nat Med 2010;16:903–908.
   PubMed Web of Science ®Google Scholar
• Ito T, Kwon HY, Zimdahl B, et al. Regulation of myeloid leukemic by the cell-fate determinant Musashi. Nature 2010;466:765–768.
   PubMed Web of Science ®Google Scholar
• Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. P Natl Acad Sci USA 2002;99:7622–7627.
   PubMed Web of Science ®Google Scholar
• Hope KJ, Cellot S, Ting SB, et al. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Stem Cells 2010;7:101–113.
   Google Scholar
• De Weer A, Speleman F, Cauwelier B, et al. EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. Haematologica 2008;93:1903–1907.
   PubMed Web of Science ®Google Scholar
• Barbouti A, Höglund M, Johansson B, et al. A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemic and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23). Cancer Res 2003;63:1202–1206.
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Nakamura Y, Yoshida T, et al. RNA-binding protein Musashi family: roles for CNS stem cells and a subpopulation of ependymal cells revealed by targeted disruption and antisense ablation. Proc Natl Acad Sci USA 2002;99:15194–15199.
   PubMed Web of Science ®Google Scholar
• Okano H, Imai T, Okabe M. Musashi: a translational regulator of cell fate. J Cell Sci 2002;115:1355–1359.
   PubMed Web of Science ®Google Scholar
• Glazer RI, Wang XY, Yuan H, et al. Musashi1: a stem cell marker no longer in search of a function. Cell Cycle 2008;7:2635–2639.
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Nakamura Y, Satoh H, et al. RNA-binding protein Musashi2: developmentally regulated expression in neural precursor cells and subpopulations of neurons in mammalian CNS. J Neurosci 2001;21:8091–8107.
   PubMed Web of Science ®Google Scholar
• Imai T, Tokunaga A, Yoshida T, et al. The neural RNA-binding protein Musashi1 translationally regulates mammalian numb gene expression by interacting with its mRNA. Mol Cell Biol 2012;21:3888–3900.
   Web of Science ®Google Scholar
• Sakata-yanagimoto M, Nakagami-Yamaguchi E, Saito T, et al. Coordinated regulation of transcription factors through Notch 2 is an important mediator of mast cell fate. Proc Natl Acad Sci USA 2008;105:7839–7844.
   PubMed Web of Science ®Google Scholar
• De Andrés-Aguayo L, Varas F, Kallin EM, et al. Musashi 2 is a regulator of the HSC compartment identified by a retroviral insertion screen and knockout mice. Blood 2011;118:554–5564.
   PubMed Web of Science ®Google Scholar
• Kaeda J, O’Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia. An attempt to define patients who may not require further therapy. Blood 2006;107: 4171–4176.
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of “real-time” quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in Leukemia--a Europe Against Cancer program. Leukemia 2003;17:2318–2357.
   PubMed Web of Science ®Google Scholar
• Kapasi AA, Singhal PC. Aging splenocyte and thymocyte apoptosis is associated with enhanced expression of p53, bax, and caspase-3. Mol Cell Biol Res Comm 1999;1:78–81.
   PubMedGoogle Scholar
• Affer M, Dao S, Liu C, et al. Gene expression differences between enriched normal and chronic myelogenous leukemia quiescent stem/progenitor cells and correlations with biological abnormalities. J Oncol 2011;2011:798592.
   PubMedGoogle Scholar
• Byers RJ, Currie T, Tholouli E, et al. MSI2 protein expression predicts unfavourable outcome in acute myeloid leukemic. Blood 2011;118:2857–2867.
   PubMed Web of Science ®Google Scholar
• Hamilton A, Helgason GV, Schemionek M, et al. Chronic myeloid leukemic stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 2012;119:1501–1510.
   PubMed Web of Science ®Google Scholar
• Crews LA, Jamieson CH. Selective elimination of leukemic stem cells: hitting a moving target. Cancer Lett 2013;338:15–22.
   PubMed Web of Science ®Google Scholar
• Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013;123:4144–4157.
   PubMed Web of Science ®Google Scholar
• Nakahara F, Sakata-Yanagimoto M, Komeno Y, et al. Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemic. Blood 2010;115: 2872–2881.
   PubMed Web of Science ®Google Scholar
• Park SM, Deering RP, Lu Y, et al. Musashi-2 controls cell fate, lineage bias, and TGF-β signaling in HSCs. J Exp Med 2014;211: 71–87.
   PubMed Web of Science ®Google Scholar
• Scheller M, Schönheit J, Zimmermann K, et al. Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med 2013;210:2239–2256.
   PubMed Web of Science ®Google Scholar
• Wang XY, Yin Y, Yuan H, et al. Musashi1 modulates mammary progenitor cell expansion through proliferin-mediated activation of the Wnt and Notch pathways. Mol Cell Biol 2008;28:3589–3599.
   PubMed Web of Science ®Google Scholar
• Peignon G, Durand A, Cacheux W, et al. Complex interplay between β-catenin signalling and Notch effectors in intestinal tumorigenesis. Gut 2011;60:166–176.
   PubMed Web of Science ®Google Scholar
• Naka K, Hoshii T, Muraguchi T, et al. TGF-beta-FOXO signalling maintains leukemia-initiating cells in chronic myeloid leukemia. Nature 2010;463:676–680.
   PubMed Web of Science ®Google Scholar